Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced the
appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and
General Counsel. Mr. Gardiner has over 25 years of experience as outside
general counsel advising private and public biotechnology companies.
“After working with Nat for so many years as our outside counsel, we are
thrilled to have him join as a permanent member of senior management,”
commented Jay R. Luly, Ph.D.
Mr. Gardiner was previously a corporate and securities law partner for
25 years, starting at Palmer & Dodge LLP and continuing through its
merger into Edwards Angell Palmer & Dodge LLP, which is now known as
Edwards Wildman Palmer LLP. Since 2008 Mr. Gardiner had been co-chair of
the firm’s Life Sciences Group, and before that he was co-chair of the
Business Law Department. In his private practice, Mr. Gardiner was
Enanta’s outside counsel and Secretary since it was founded, and he led
its IPO legal team. He also serves as a Trustee of Joslin Diabetes
Center, Inc. in Boston, where he is a member of the Executive Committee
and Chair of the Compensation Committee.
Mr. Gardiner received his A.B. from Harvard College and his J.D. from
the University of Virginia School of Law.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase – as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140512005177r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2014